Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: Implications for chemotherapy selection

Cancer Research

Volumn 69, Issue 3, 2009, Pages 1055-1062

  Broët, Philippe ^a,b,h   Camilleri Broët, Sophie ^a,b,c   Zhang, Shenli ^d   Alifano, Marco ^a,b   Bangarusamy, Dhinoth ^e   Battistella, Maxime ^b   Wu, Yonghui ^f   Tuefferd, Marianne ^a   Régnard, Jean François ^b,c   Lim, Elaine ^d   Tan, Patrick ^e,f   Miller, Lance D ^e,g  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e GENOME INSTITUTE OF SINGAPORE   (Singapore)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE NUMBER; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TRANSCRIPTOMICS;

ADENOCARCINOMA; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOME ABERRATIONS; COHORT STUDIES; COMPARATIVE GENOMIC HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 59149096811     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1116     Document Type: Article

References (37)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
2. Adebonojo SA, Bowser AN, Moritz DM, Corcoran PC. Impact of revised stage classification of lung cancer on survival: a military experience. Chest 1999;115:1507-13.
3. Wakeleea H, Dubeyb S, Gandarac D. Optimal adjuvant therapy for non-small cell lung cancer - how to handle stage I disease. Oncologist 2007;12:331-7.
4. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. Oncogene 2002;21:6877-83.
5. Kim TM, Yim SH, Lee JS, et al. Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res 2005;11:8235-42.
6. Gelsi-Boyer V, Orsetti B, Cervera N, et al. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res 2005;3:655-67.
7. Pollack JR, Sorlie T, Perou CM, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 2002;99:12963-8.
8. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology and genetics: tumors of the lung, pleura, thymus, and heart. Geneva: IARC Press; 2004.
9. Ishkanian AS, Malloff CA, Watson SK, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 2004;36:299-303.
10. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
11. Broët P, Richardson S. Detection of gene copy number changes in CGH microarrays using a spatially correlated mixture model. Bioinformatics 2006;22:911-8.
12. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
13. McLachlan GJ, Peel D. Finite mixture models. New York: Wiley; 2000.
14. Gilks WR, Richardson S, Spiegelhalter DJ. Markov chain Monte Carlo in practice. London: Chapman & Hall; 1996.
15. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-37.
16. Broët P, Lewin A, Richardson S, Dalmasso C, Magdelenat H. A mixture model-based strategy for selecting sets of genes in multiclass response microarray experiments. Bioinformatics 2004;20:2562-71.
17. Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc B 1972;74:187-220.
18. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
19. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006;66:7466-72.
20. Simon R, Korn E, McShane L, Radmacher M, Wright G, Zhao Y. Design and analysis of DNA microarray investigations. New York: Springer-Verlag; 2003. p. 96-119.
21. Tukey JW. Tightening the clinical trial. Control Clin Trials 1993;14:266-85.
22. Peto R, Peto J. Asymptotically efficent rank. invariant test procedures (with discussion). J Royal Stat Soc A 1972;135:185-207.
23. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
24. Moro-Sibilot D, Aubert A, Diab S, et al. Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer. Eur Respir J 2005;26:480-6.
25. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-62.
26. Garnis C, Lockwood WW, Vucic E, et al. High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 2006;118:1556-64.
27. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-8.
28. Tonon G, Wong KK, Maulik G, et al. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 2005;102:9625-30.
29. Chesi M, Leif Bergsagel P, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998;91:4457-63.
30. Leoutsakou T, Talieri M, Scorilas A. Prognostic significance of the expression of SR-A1, encoding a novel SR-related CTD-associated factor, in breast cancer. Biol Chem 2006;387:1613-8.
31. Tatenhorst L, Senner V, Püttmann S, Paulus W. Regulators of G-protein signaling 3 and 4 (RGS3, RGS4) are associated with glioma cell motility. J Neuropathol Exp Neurol 2004;63:210-22.
32. Souazé F, Dupouy S, Viardot-Foucault V, et al. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res 2006;66:6243-9.
33. Vartiainen MK, Sarkkinen EM, Matilainen T, Salminen M, Lappalainen P. Mammals have two twinfilin isoforms whose subcellular localizations and tissue distributions are differentially regulated. J Biol Chem 2003;278:34347-55.
34. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98:13790-5.
35. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80.
36. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
37. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001;98:13784-9.